Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
The purpose of this study is to compare the presence, degree, time course and profile of
opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine
or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome
measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal
Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate
an opioid withdrawal syndrome.
Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1
National Institute on Drug Abuse (NIDA)
Phase 1/Phase 2
The purpose of this study is to compare subject response to liquid vs. tablet formulations,
to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to
evaluate if dose response curve for tablet is equal to liquid form."
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.